Actavis posts Q4 loss despite sales growth; Vanda awareness push raises expert ire; FDA, EMA plan closer work on safety;

@FiercePharma: Best-read on the site yesterday, back for Day 2: Actavis inks $25B deal for Forest in bid to build its brand stable. More | Follow @FiercePharma

@TracyStaton: BioMarin's $380K price tag on Vimizim is high, but far from the highest. More | Follow @TracyStaton

@EricPFierce: New York AG says Teva, Ranbaxy were on a collusion course with pay-to-delay deals. Yesterday's story | Follow @EricPFierce

@CarlyHFierce: Tops on FiercePharmaMarketing yesterday: Eisai's revved-up Belviq marketing starting to pay off, analysts say. Story | Follow @CarlyHFierce

> Despite strong sales growth, Actavis ($ACT) dipped into the red for the fourth quarter, thanks to restructuring and other charges; the company won't issue a 2014 forecast till its $25 billion Forest Laboratories ($FRX) buyout closes later this year. Report

> A Vanda Pharmaceuticals ($VNDA) disease awareness campaign for 24-hour sleep-wake disorder is raising eyebrows because it only affects a small percentage of blind people; Vanda recently won FDA approval for its Hetlioz treatment for the disorder. Report

> The FDA and its trans-Atlantic counterpart, the European Medicines Agency (EMA), plan to work more closely on medicines safety through regular collaborative meetings. Report

> Cipla inked a strategic partnership with Merck's ($MRK) Indian business to market the latter's HIV drug raltegravir in the country. Report

> Bayer HealthCare launched a global late-stage trial of Stivarga (regorafenib) in patients with colorectal cancer whose disease has spread to the liver. Report

Medical Device News

@FierceMedDev: S&N isn't the only one pursuing M&A to boost its sports medicine device offerings. Stryker is doing same. More | Follow @FierceMedDev

@MarkHFierce: Medtronic said its tiny wireless pacer has been implanted in its first U.S. patient. Release | Follow @MarkHFierce

@MichaelGFierce: BioMérieux's BioFire sets course for GI panel FDA clearance. Article | Follow @MichaelGFierce

> Syneron's revenue dips in Q4, but an aesthetic laser M&A deal gives a boost. Story

> A French outfit focused on medical imaging components is making inroads in China. Item

Biotech News

@FierceBiotech: Investigators: Personalized T cell attack spurs complete remissions of leukemia. Article | Follow @FierceBiotech

@JohnCFierce: Can a patient's dad succeed at Duchenne muscular dystrophy after all the biotech failures? Story | Follow @JohnCFierce

@DamianFierce: Raptor's Huntington's drug slowed the disease in a subset of patients, and that was enough to elate investors. News | Follow @DamianFierce

@EmilyMFierce: Gene therapy shows promise for treating heart attack victims. More from Scientific American | Follow @EmilyMFierce

> Is it news to you? Furiex really is up on the auction block. More

> Onconova hammered after top drug rigosertib flunks key PhIII study. Piece

Pharma Manufacturing News

> 13 drugmakers picked for FDA's special import perks. Story

> Cold-chain costs were halved in African vaccine campaign. Article

> Excipient makers jump on audits as new regs kick in. News

> GSK plant goes more than three years without plant injury. More

> West Pharmaceutical benefits from emerging market growth. Piece

> India pressures Merck and GSK on vaccine prices. Item

Vaccines News

> Dynavax's hep B vaccine plans derailed by European request for extra safety data. Report

> Novartis' Bexsero sparks debate about transatlantic vaccine approvals. Article

> WHO reports success in distributing vaccines at ambient temperatures. More

> CDC researchers say measles outbreaks cost U.S. health authorities up to $5M in 2011. News

> Chinese researchers see pandemic potential in bird flu virus reassortment. Story

> India is pushing GSK and Merck to slash the cost of HPV vaccines. Item

And Finally... Your smartphone keeps you connected to everything else. Why not your toothbrush? Report

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.